ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease